Affinity Technologies, Inc. ( ($BIAF) ) has issued an announcement. On October 13, 2026, bioAffinity Technologies announced it will present new research data at ...

Findings report on ability to measure cellular and soluble inflammatory protein biomarkers in sputum, including biologic drug targets Company advances research and development in diagnostic tests ...

SAN ANTONIO, November 05, 2025--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases ...

The Japanese Patent Office has signalled its intention to grant patent protection for bioAffinity Technologies’ noninvasive ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

There is no blood test, including a complete blood count (CBC), that can diagnose lung cancer on its own. Low-dose CT (LDCT) scans are the gold standard for early lung cancer detection and can reduce ...

SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced that unit ...

Companies debut federal distribution collaboration to VA leadership, administrators and physicians at NAVREF 2026.

One reason is that too few clinicians raise the issue with their patients. New research published in the American Journal of Surgery indicates that only about 1 in 6 patients eligible for lung cancer ...

Cizzle Biotechnology has moved its CIZ1B biomarker blood test into commercialisation after securing US clinical accreditation ...

Share on Pinterest A new screening test could help diagnose lung cancer earlier than traditional CT scans. Andriy Onufriyenko/Getty Images About 1.8 million deaths each year are attributable to lung ...